June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Evaluation of the efficacy of mouse opsin promoter for rhodopsin gene augmentation in dogs
Author Affiliations & Notes
  • Raghavi Sudharsan
    Clinical Studies, University of Pennsylvania, Philadelphia, PA
  • Simone Iwabe
    Clinical Studies, University of Pennsylvania, Philadelphia, PA
  • Tatyana Appelbaum
    Clinical Studies, University of Pennsylvania, Philadelphia, PA
  • Alfred S Lewin
    Molecular Genetics and Microbiology, University of Florida, Gainesville, FL
  • William W Hauswirth
    Ophthalmology, University of Florida, Gainesville, FL
  • Gustavo D Aguirre
    Clinical Studies, University of Pennsylvania, Philadelphia, PA
  • William A Beltran
    Clinical Studies, University of Pennsylvania, Philadelphia, PA
  • Footnotes
    Commercial Relationships Raghavi Sudharsan, None; Simone Iwabe, None; Tatyana Appelbaum, None; Alfred Lewin, None; William Hauswirth, AGTC Inc. (P); Gustavo Aguirre, None; William Beltran, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raghavi Sudharsan, Simone Iwabe, Tatyana Appelbaum, Alfred S Lewin, William W Hauswirth, Gustavo D Aguirre, William A Beltran; Evaluation of the efficacy of mouse opsin promoter for rhodopsin gene augmentation in dogs. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5408.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: An AAV2/5 carrying human Rhodopsin (hRHO) cDNA under the control of a mouse opsin promoter (mOP) did not prevent light-induced retinal degeneration in the light-sensitive canine model of autosomal dominant Retinitis Pigmentosa (ADRP) (Iwabe et al, ARVO 2014). We now have evaluated in canine retinas the levels of rhodopsin expression following treatment with this same viral vector construct to determine the lack of rescue effect.

Methods: Wild-type dogs were used; an AAV2/5-mOP-hRHO construct was subretinally injected (150 ul at 5x1012 vg/ml) in 5 eyes, and one eye received equal volume of BSS. Dogs were euthanatized 8-9 weeks post injection. Punches of neuroretina (3 mm diameter) were collected from the bleb (treated) and non-injected areas, and used to analyze levels of expression of hRHO transgene by western blot and qRT-PCR. RHO protein levels were evaluated using an antibody that recognizes both canine and human proteins. Transcription of hRHO was evaluated by RT-PCR using a set of primers specific to hRHO. In addition, absolute quantitation was performed using the qRT-PCR Standard Curve method to determine the absolute amounts of human versus endogenous canine RHO mRNA transcribed.

Results: No significant differences in total RHO protein amounts between treated and non-treated regions were found by western blotting. Transcription of hRHO in bleb regions retina was confirmed based on Ct values obtained with hRHO specific primers. However, using absolute quantitation, we determined that the hRHO transgene was being transcribed at only 1-4% of the mRNA levels of the endogenous canine RHO.

Conclusions: A similar AAV construct as used here has been previously shown to efficiently augment RHO expression in the transgenic P23H mouse model of ADRP, yielding a two-fold increase in total RHO mRNA, and a 1.5 times increase in protein (Mao et. al., Hum. Gene Ther., 2011). In the canine retina, our current results show that hRHO transgene expression is low, thus explaining the lack of rescue effect in the canine T4R RHO model of ADRP that we had previously reported. This may be due either to limited efficiency of the mouse opsin promoter, or to instability of hRHO transcripts in the canine retina. Ongoing studies now focus on the human opsin promoter instead, and adding enhancer elements to the viral construct to improve transgene expression.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.